Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study | Synapse
April 25, 2026Open Access
Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study
Key Points
This study aims to evaluate the safety and effectiveness of focused ultrasound ablation combined with immune checkpoint inhibitors in treating non-small cell lung cancer with liver metastases.
Conducted a feasibility study focusing on patients with driver-gene wild-type NSCLC and liver metastasis.
Utilized focused ultrasound ablation surgery followed by immune checkpoint inhibition therapy.
Assessed safety, activity, and overall feasibility of the combined treatment.
Preliminary findings indicate promising safety and activity of combined treatments.
Further validation of the results is required to confirm the efficacy of this approach.
Abstract
FUAS sequential with ICIs suggests preliminary safety, activity and feasibility in treating driver-gene wild-type NSCLC patients with liver metastases, further validation is needed.